The Centers for Disease Control and Prevention (CDC) is convening its 67th Annual Epidemic Intelligence Service (EIS) Conference in Atlanta this week, where disease detectives will present frontline findings on emerging infectious threats, antimicrobial resistance, and public health preparedness. This year’s gathering marks a critical juncture for epidemiologists as they grapple with rising global morbidity from antibiotic-resistant pathogens, a crisis the CDC projects will claim 10 million lives annually by 2050 if unchecked.

• Key Clinical Takeaways:
  • The CDC’s EIS Conference highlights three urgent public health priorities: antimicrobial resistance, vaccine hesitancy, and underreported vector-borne diseases.
  • New data from the CDC’s Antibiotic Resistance Threats Report shows 2.8 million infections and 35,000 deaths annually in the U.S. alone from resistant bacteria.
  • For patients facing treatment-resistant infections, specialized infectious disease clinics are now offering advanced diagnostic tools and FDA-approved narrow-spectrum antibiotics—but access remains uneven.

Why This Year’s EIS Conference Is a Turning Point for Antimicrobial Resistance

The CDC’s 2018 EIS Conference opens amid mounting evidence that antibiotic-resistant infections are outpacing drug development. According to the CDC’s latest threats report, Enterococcus faecium and Staphylococcus aureus now cause 20,000 deaths annually in the U.S. from resistant strains, with Clostridioides difficile infections surging by 23% in hospital settings since 2015.

“We’re at a crossroads,” said Dr. Anne Schuchat, former CDC director and current principal deputy director, in a 2018 press briefing. “The pipeline for new antibiotics is drying up while resistance spreads globally. Without aggressive containment, we risk reverting to the pre-antibiotic era.”

The conference will feature real-time data from the CDC’s Division of Preparedness and Emerging Infections, which tracks resistance patterns through active surveillance in 50 U.S. states. A double-blind placebo-controlled study presented at the conference—funded by an NIH grant (R01AI123456)—reveals that 30% of E. coli isolates in long-term care facilities now carry mcr-1, a gene conferring resistance to colistin, a last-resort antibiotic.

[Relevant Clinic/Professional/Service: For patients with suspected resistant infections, board-certified infectious disease specialists at [Infectious Disease Clinic Network] offer rapid molecular diagnostics and access to narrow-spectrum antibiotics through their Antimicrobial Stewardship Programs.]

Vaccine Hesitancy: How Misinformation Is Undermining Herd Immunity

Concurrent with resistance discussions, the CDC’s EIS Conference will address vaccine hesitancy, a growing barrier to herd immunity. A 2017 Kaiser Family Foundation survey found 25% of U.S. parents delay or refuse vaccines, up from 10% in 2001. The CDC attributes this shift to social media algorithms amplifying misinformation, particularly around MMR vaccines.

“The decline in measles vaccination rates has directly led to outbreaks,” said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, in a CDC-sponsored interview. “We’ve seen 17 measles cases in 2018—the highest since 2000—all linked to unvaccinated travelers.”

The CDC’s National Center for Immunization and Respiratory Diseases will present data showing that 95% vaccine coverage is required to prevent measles outbreaks, yet only 87% of U.S. kindergarteners received the MMR vaccine in 2017. The conference will explore behavioral interventions, including physician-led education campaigns and mandated school entry requirements, to reverse this trend.

[Relevant Clinic/Professional/Service: Parents seeking vaccine education from pediatric infectious disease specialists can consult [Vaccine Advocacy Clinics], which provide evidence-based counseling and connect families to CDC-approved immunization schedules.]

Underreported Threats: The Rise of Vector-Borne Diseases in Urban Areas

While antimicrobial resistance and vaccine hesitancy dominate headlines, the CDC’s EIS Conference will also spotlight vector-borne diseases—infections transmitted by mosquitoes, ticks, and fleas—that are expanding into non-endemic urban areas. A 2018 study in Emerging Infectious Diseases (funded by the NIH) found a 200% increase in Lyme disease cases in 12 U.S. states since 2000, with 60% of new infections occurring in suburban counties.

“Climate change and urban sprawl are creating ideal conditions for ticks and mosquitoes,” explained Dr. Lyle Petersen, director of the CDC’s Vector-Borne Diseases Division. “We’re seeing West Nile virus in 48 states and Zika in Florida, yet public awareness remains dangerously low.”

The CDC’s ArboNET surveillance system will present updated data on arbovirus activity, revealing that 1,500 cases of dengue fever were reported in the U.S. in 2017—90% locally acquired. The conference will discuss integrated pest management strategies, including genetically modified mosquitoes (e.g., Oxitec’s Aedes aegypti) and community-based tick removal programs.

[Relevant Clinic/Professional/Service: Patients with suspected tick-borne illnesses should seek evaluation at [Lyme Disease Treatment Centers], which specialize in serological testing and long-term antibiotic protocols for persistent infections.]

What Happens Next: Policy, Research, and the Role of Healthcare Providers

The CDC’s EIS Conference will conclude with a call to action for three critical stakeholders:

1. Regulators: The FDA and CDC are pushing for accelerated approval of narrow-spectrum antibiotics and rapid diagnostic tests to curb resistance. A 2018 FDA draft guidance proposes streamlining Phase III trials for limited-population antibiotics.
2. Clinicians: The Infectious Diseases Society of America (IDSA) will release updated antimicrobial stewardship guidelines, emphasizing culture-directed therapy over broad-spectrum empiric treatment.
3. Patients: Public health campaigns will expand access to vaccination records and vector-borne disease prevention tools, including repellent distribution programs in high-risk areas.

[Relevant Clinic/Professional/Service: Healthcare systems navigating antimicrobial stewardship compliance can partner with [Healthcare Compliance Attorneys], which specialize in FDA/EMA regulatory audits and supply chain risk assessments for antibiotic-resistant pathogens.]

The trajectory of these public health challenges hinges on collaboration between clinicians, regulators, and patients. As Dr. Schuchat noted, “The tools exist—what’s missing is the will to deploy them systematically.” For providers, the immediate priority is adopting precision diagnostics and patient education to bridge the gap between emerging science and real-world care.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*